Global Information
회사소개 | 문의 | 위시리스트

브래디키닌 B1 수용체(B1R) : 파이프라인 리뷰

Bradykinin B1 Receptor (B1R) - Pipeline Review, H1 2019

리서치사 Global Markets Direct
발행일 2019년 03월 상품 코드 358701
페이지 정보 영문 36 Pages
가격
US $ 3,500 ₩ 4,222,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,445,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,668,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


브래디키닌 B1 수용체(B1R) : 파이프라인 리뷰 Bradykinin B1 Receptor (B1R) - Pipeline Review, H1 2019
발행일 : 2019년 03월 페이지 정보 : 영문 36 Pages

브래디키닌 B1 수용체는 BDKRB1 유전자에 의해서 코드된 단백질 공역 수용체(GPCR)입니다. 그 리간드는 병태생리학적 상태(염증, 외상, 화상, 쇼크, 알레르기 등)로 생성되는 브래디키닌입니다.

브래디키닌 B1 수용체(B1R) 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

목차

서론

개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 분야별
  • 개발중인 제품 : 적응별

파이프라인 제품 개요

  • 초기 단계 제품

개발중인 제품 : 기업별

개발중인 제품 : 대학/연구기관별

치료제 평가

  • 단독치료 제품/병용 제품별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • Axxam SpA
  • Boehringer Ingelheim GmbH
  • Dompe Farmaceutici S.p.A.
  • Grunenthal GmbH

약제 개요

휴지 상태 프로젝트

개발이 중지된 제품

최신 뉴스와 프레스 릴리스

부록

도표

KSM 16.07.21

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Axxam SpA, H1 2016
  • Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Pipeline by Dompe Farmaceutici S.p.A., H1 2016
  • Pipeline by Grunenthal GmbH, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016

Summary:

Global Markets Direct's, 'Bradykinin B1 Receptor (B1R) - Pipeline Review, H1 2016', provides in depth analysis on Bradykinin B1 Receptor (B1R) targeted pipeline therapeutics.

The report provides comprehensive information on the Bradykinin B1 Receptor (B1R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Bradykinin B1 Receptor (B1R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Bradykinin B1 Receptor (B1R)
  • The report reviews Bradykinin B1 Receptor (B1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Bradykinin B1 Receptor (B1R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Bradykinin B1 Receptor (B1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Bradykinin B1 Receptor (B1R) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bradykinin B1 Receptor (B1R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bradykinin B1 Receptor (B1R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bradykinin B1 Receptor (B1R) Overview
  • Therapeutics Development
    • Bradykinin B1 Receptor (B1R) - Products under Development by Stage of Development
    • Bradykinin B1 Receptor (B1R) - Products under Development by Therapy Area
    • Bradykinin B1 Receptor (B1R) - Products under Development by Indication
  • Bradykinin B1 Receptor (B1R) - Pipeline Products Glance
    • Early Stage Products
  • Bradykinin B1 Receptor (B1R) - Products under Development by Companies
  • Bradykinin B1 Receptor (B1R) - Products under Development by Universities/Institutes
  • Bradykinin B1 Receptor (B1R) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bradykinin B1 Receptor (B1R) - Companies Involved in Therapeutics Development
    • Axxam SpA
    • Boehringer Ingelheim GmbH
    • Dompe Farmaceutici S.p.A.
    • Grunenthal GmbH
  • Bradykinin B1 Receptor (B1R) - Drug Profiles
    • BI-113823 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Bradykinin B1 Receptor for Chronic Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize BDKRB1 for Pain and Ophthalmic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize BKB1R for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Antagonize Bradykinin B1 Receptor for Respiratory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bradykinin B1 Receptor (B1R) - Dormant Projects
  • Bradykinin B1 Receptor (B1R) - Discontinued Products
  • Bradykinin B1 Receptor (B1R) - Featured News & Press Releases
    • May 05, 2014: Possible Treatment for Kidney Disease in Lupus Studied at UH
    • Feb 07, 2014: Researchers Exploring Treatment For Lupus-Based Kidney Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer
Back to Top
전화 문의
F A Q
 
BCC Research